TREATMENT OF PATIENTS WITH FAMILIAL DEFECTIVE APOLIPOPROTEIN B-100 WITH PRAVASTATIN AND GEMFIBROZIL - A 2-PERIOD CROSS-OVER STUDY

被引：9

作者：

HANSEN, PS ^{[1
]}

MEINERTZ, H ^{[1
]}

GERDES, LU ^{[1
]}

KLAUSEN, IC ^{[1
]}

FAERGEMAN, O ^{[1
]}

机构：

[1] RIGSHOSP,DEPT MED B,COPENHAGEN,DENMARK

来源：

CLINICAL INVESTIGATOR | 1994年 / 72卷 / 12期

关键词：

FAMILIAL DEFECTIVE APOLIPOPROTEIN B-100; DRUGS; CLINICAL TRIAL; LIPOPROTEIN; PRAVASTATIN; GEMFIBROZIL;

D O I：

10.1007/BF00577757

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Thirty patients with familial defective apolipoprotein B-100 were treated in a two-period (8 weeks each) cross-over study with pravastatin and gemfibrozil. Cholesterol, LDL cholesterol, and apo B were reduced by 20-25% (P < 10(-4)) by pravastatin and by 4-6% by gemfibrozil (pravastatin vs. gemfibrozil: P < 10(-4)). Response to pravastatin was variable and not correlated to gender, age, or apo E genotype. Gemfibrozil lowered triglycerides by 25% (P < 10(-4)) and raised HDL cholesterol by 11%. The effects of pravastatin on these two interrelated variables were significantly smaller. Both drugs increased Lp(a) significantly by about 10%. The LDL cholesterol lowering effect of pravastatin in patients with FDB is similar to that observed in patients with familial hypercholesterolemia.

引用

页码：1065 / 1070

页数：6

共 36 条

[1] ARAD Y, 1990, J LIPID RES, V31, P567
[2] ARMITAGE P, 1987, STATISTICAL METHODS, P222
[3] MEVINOLIN AND COLESTIPOL STIMULATE RECEPTOR-MEDIATED CLEARANCE OF LOW-DENSITY LIPOPROTEIN FROM PLASMA IN FAMILIAL HYPERCHOLESTEROLEMIA HETEROZYGOTES
BILHEIMER, DW
GRUNDY, SM
BROWN, MS
GOLDSTEIN, JL
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1983, 80 (13): : 4124 - 4128
[4] BIMMERMANN A, 1991, CURR THER RES CLIN E, V49, P635
[5] THE RESPONSE TO LOVASTATIN TREATMENT IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IS MODULATED BY APOLIPOPROTEIN-E POLYMORPHISM
CARMENA, R
ROEDERER, G
MAILLOUX, H
LUSSIERCACAN, S
DAVIGNON, J
[J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 1993, 42 (07): : 895 - 901
[6] CORESH J, 1993, J LIPID RES, V34, P1687
[7] ENDO A, 1992, J LIPID RES, V33, P1569
[8] FARMER JA, 1992, CLIN THER, V14, P708
[9] FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
[10] HANSEN PS, 1991, J LIPID RES, V32, P1229

← 1 2 3 4 →